This conference will discuss rare metabolic disorders, their detection, current research, disease management and treatment. With a number of sessions over three days, many aspects of the metabolome will be covered, bringing together those working in academia, medicine, biotechnology and pharmaceuticals from all over the world.
Metabolic diseases disrupt normal metabolism which is the process of converting food to energy on a cellular level. They affect the ability of the cell to perform critical biochemical reactions that involve the processing or transport of proteins, carbohydrates, or lipids.
Most metabolic diseases are inherited disorders and are caused by mutations that result in incorrectly functioning or missing enzymes that are needed for cells to perform metabolic processes. There are a large number of metabolic diseases, disorders and conditions that affect a vast array of areas of the body from the respiratory system to the eyes.
Dr. Umur A. Kayabasi, from the Lifemed Health Center in Turkey, will be discussing the “Recent Advances in the Treatment of Mitochondrial Ophthalmic Diseases.” He will be focussing on two diseases in particular: Chronic Progressive External Ophthalmoplegia and Leber’s Hereditary Optic Neuropathy. “There are extremely important developments in both conditions which were incurable until recently. For CPEO, there is a very promising drug therapy trial going on in the US and for LHON, gene therapy trials have started in Paris”. Dr Kayabasi will be giving the initial results of these novel treatments.
Some metabolic disorders can be treated if diagnosed early and if treatment is started at a young age. However, others have no effective therapy and can cause severe problems, despite early diagnosis. Therefore there is a lot of research being conducted into novel treatments in many areas, including gene therapy.
Rare Metabolic Disorders 2016 will explore some of these new options through various talks over the three days. Dr Takis Athanasopoulos, University of London, will be speaking about “Gene and Cell therapy approaches for rare diseases,” Dr Martino Picardo, Stevenage Bioscience Catalyst, will be discussing “The role of Open Innovation in development of new therapies for rare diseases,” and Dr Adina Milac, Institute of Biochemistry of the Romanian Academy, will explore “Computational approaches to targeted drug design in metabolic diseases.”
Treating metabolic disorders requires a wholesome approach whereby non-medicinal treatment may also be needed in order to restore quality of life. Familial dysautonomia (FD) is a rare genetic disease that impairs vital functions and causes neural and motor deficiency. These deficiencies are often characterised by static and dynamic instability as well as by osteoporosis. As a result people with FD are at a high risk of falls, physical impairment and fractures.
There will be a whole session on FD with a number of speakers discussing the disease, its detection and research into treatment. As well as novel medicinal treatments, novel ways to use technology for therapeutic effects are being developed to help treat FD.
Rosalee Gefen, from The Zinman College of Physical Education & Sport Sciences in Israel, will be speaking about a new mobile application for balance training in people with Familial dysautonomia. She said “Balance training for people with FD poses unique challenges so there is a need for ways to deliver active balance training to these individuals in a safe and feasible manner. As they rely mainly on vision for balance, an iPhone application was designed to train balance by interfering with the anticipatory processing of visual information, therefore challenging the somatosensory and vestibular system to supply information.”
Meeting description: From congenital disorders to inherited metabolic diseases, this event will investigate recent developments in an informal academic setting, with an atmosphere conducive to debate and discussion. With a number of sessions over three days, many aspects of the metabolome will be covered, bringing together those working in academia, medicine, biotechnology and pharmaceuticals.
- The deadline for abstract submissions for oral presentation is June 10th 2016
- The early registration deadline is 30th July 2016
- The deadline for abstract submissions for poster presentation is September 6th 2016
Rare Metabolic Disorders has an open abstract session. Abstracts can be submitted on any subject related to metabolic research or metabolomics.
|Enzyme replacement therapy for lysosomal storage disorders: the pharmacology of marginal gains||Dr Robin Lachmann||National Hospital for Neurology and Neurosurgery||United Kingdom|
|Biochemical insights into Primary hyperoxaluria type III||Dr Kerry Loomes||University of Auckland||New Zealand|
|Plasma miRNA signatures for following the neoplastic process in hereditary tyrosinemia||Professor Robert M. Tanguay||Université Laval||Canada|
|Steroid profiling for rare diseases||Dr Bruno Vogt, Inselspital||University Hospital of Bern||Switzerland|
|GRK2 as a new integrative node in obesity and insulin resistance: multi organ effects||Dr Cristina Murga||Centro de Biología Molecular Severo Ochoa (CSIC-UAM)||Spain|
|Mobile application for balance training, in people with familial dysautonomia: three case reports||Rosalee Gefen||The Zinman College of Physical Education & Sport Sciences||Israel|
|Next Generation Sequencing (NGS) approach to discovery of rare neuro-metabolic disorders||Dr. Maja Tarailo-Graovac||Centre for Molecular Medicine and Therapeutics||Canada|
|B12 deficiency and Gestational diabetes – an update||Dr Vimal Karani S||University of Reading||United Kingdom|
|Alkaptonuria - Metabolic response to treatment with Nitisinone||Dr Anna M Milan||Royal Liverpool and Broadgreen University Hospitals||United Kingdom|
|Using Dried Blood Spot Testing in the management of Tyrosinaemia Type 1||Dr Roshni Vara||St Thomas’ Hospital||United Kingdom|
|Role and regulation of the RNA-binding protein Bicc1 in cystic kidney diseases||Professor Daniel Constam||Ecole Polytechnique Fédérale de Lausanne||Switzerland|
|Respiratory Problems in Familial Dysautonomia||Professor Channa Maayan||Hadassah Medical Center||Israel|
|Managing Familial Dysautonomia in a North London DGH: A paediatrician's steep learning curve||Dr Su Laurent||Royal Free London NHS Foundation Trust||United Kingdom|
|Autonomic Dysfunction in Familial Dysautonomia||Dr Ellen Merete Hagen||Consultant Neurologist, Autonomic Unit||United Kingdom|
|Innovative treatment of the porphyrias||Dr. Elisabeth Minder||Stadtspital Triemli - Stadt Zürich||Switzerland|
|Biliary transporter mutations; implications for gestational liver disease||Professor Catherine Williamson||King's College London||United Kingdom|
|The impact of genomics on rare disease research||Dr Jonathan Milner,||Deputy Chairman, Abcam plc||United Kingdom|
|Gene and Cell therapy approaches for Rare Diseases||Dr Takis Athanasopoulos||University of London||United Kingdom|
|Computational approaches to targeted drug design in metabolic diseases||Dr Adina Milac||Biochemistry of the Romanian Academy||Romania|
|The molecular basis of childhood-onset mitochondrial diseases’ for ~30 minutes||Professor Shamima Rahman||Institute of Child Health||United Kingdom|
|Familial Dysautonomia: Genotype, Phenotype and Translational Research||Dr Lucy Norcliffe-Kaufmann||New York University||United States|
|The role of Open Innovation in development of new therapies for rare diseases||Dr Martino Picardo||Stevenage Bioscience Catalyst||United Kingdom|
|Treatable Neurometanolic Diseases in the 21st Century||Dr. Clara van Karnebeek||University of British Columbia||Canada|
|Neurometabolic Disorders in Children||Dr. Germaine Pierre||UHBT, Education Centre||United Kingdom|
|DevelopAKUre: a patient-led clinical trial for a rare disease||Oliver Timmis||AKU Society||United Kingdom|
|EU funding of rare diseases research: rare metabolic disorders in the spotlight||Dr Egle Simelyte||AKU Society||United Kingdom|
|Recent Advances in the Treatment of Mitochondrial Ophthalmic Diseases||Dr. Umur Kayabasi||Lifemed Health Center, Uskudar University,||Turkey|
Phone:?(+44) 020 7183 82 31
Venue, Accommodation and Travel Details
This event will be held at Cineworld: The O2 Peninsula Square London SE10 0DX United Kingdom
Once inside the O2 building please make your way to Cineworld. A map of the O2 can be found by clicking here
For more detailed travel information click here
For accommodation suggestions click here
Abstract and Poster Presentations
All abstracts accepted for oral presentation are also automatically accepted for poster presentation
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
You can either use your Paypal account or click on the no account link to pay directly by credit or debit card
We do not store credit card details nor do we share customer details with any 3rd parties
If you wish to pay by?cheque, purchase order?or?bank transfer, please contact sales [@] euroscicon.com